Overall market sentiment has been high on X4 Pharmaceuticals Inc (XFOR) stock lately. XFOR receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
X4 Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on XFOR!
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With XFOR Stock Today?
X4 Pharmaceuticals Inc (XFOR) stock is trading at $1.43 as of 11:06 AM on Thursday, Sep 29, a decline of -$0.02, or -1.38% from the previous closing price of $1.45. The stock has traded between $1.41 and $1.67 so far today. Volume today is 768,511 compared to average volume of 980,727.
To screen for more stocks like X4 Pharmaceuticals Inc click here.
More About X4 Pharmaceuticals Inc
X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Its product candidate, X4P-001, has completed a Phase 2 trial in patients with a rare genetic PI called Warts. The company is also developing X4P-002, a CXCR4 antagonist that has properties that could enable penetration of the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers, including glioblastoma multiforme.
Click Here to get the full Stock Report for X4 Pharmaceuticals Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
